Bhettay 1978.

Methods	Allocation: randomised Blinding: double‐blind Controlled: placebo Centre: multicentre Arm: 2 arms, cross‐over design
Participants	Inclusion criteria: children with juvenile chronic arthritis Exclusion criteria: known history of contraindications to study drugs; receiving gold, d‐penicillamine, or corticosteroids; in a state of remission Baseline characteristics N = 30 Age: mean not reported, range 2 to 16 years Gender: male (unstated); female (unstated) Number randomised: intervention (15); control (15) Number completed: intervention (15); control (15) Setting and location: South Africa
Interventions	Intervention group (N = 15): indomethacin (2 weeks), cross‐over ketoprofen (2 weeks) Control group (N = 15): ketoprofen (2 weeks), cross‐over indomethacin (2 weeks) Participants < 20 kg: ketoprofen 25 mg capsule twice daily; participants > 20 kg: ketoprofen capsules x 2 = 50 mg twice daily Participants < 20 kg: indomethacin 25 mg capsule twice daily; participants > 20 kg: indomethacin capsules x 2 = 50 mg twice daily Study duration: 5 weeks
Outcomes	Primary outcomes Severity of pain: morning stiffness; interference with function; general feeling of well‐being; symptoms interpreted by the participant that were due to treatment; preference of either drug Articular index 0 to 4: passive movement of a joint; knee score; combined finger‐joint circumference Grip strength Temporomandibular joint Patient Impression of Change (5‐point scale) Fever, rash, splenomegaly, or lymphadenopathy Investigator's impression of change Secondary outcomes Side effects Amount of rescue analgesia
Notes	Sources of funding: Maybaker (SA) (Pty) Ltd provided drug supplies.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: Randomised drug administration, not participants
Allocation concealment (selection bias)	Unclear risk	Comment: Insufficient information
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: Insufficient information
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Quote: Insufficient information
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: All participants were accounted for. Lost to follow‐up and withdrawals explained.
Selective reporting (reporting bias)	Unclear risk	Comment: Means and standard deviations not reported, nor blood sedimentation rate, haemoglobin level, platelet and white cell count.
Size	High risk	Comment: Total participants = 30 (< 50 per treatment arm)
Other bias	Low risk	Comment: No other potential sources of bias found.